©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
The Three -Adrenergic Receptor Subtypes Achieve Basolateral Localization in Madin-Darby Canine Kidney II Cells via Different Targeting Mechanisms (*)

(Received for publication, November 7, 1995; and in revised form, December 13, 1995)

Magdalena Wozniak (§) Lee E. Limbird (¶)

From the Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6600

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
SUMMARY
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The present studies examined the localization of the alpha- and alpha-adrenergic receptor (AR) subtypes in polarized Madin-Darby canine kidney cells (MDCK II) and the mechanisms by which this is achieved. Previously we demonstrated that the alphaAR subtype is directly delivered to lateral subdomain of MDCK II cells. Surface biotinylation strategies demonstrated that the alphaAR, like the alphaAR, achieves 85-90% basolateral localization at steady-state. However, in contrast to the alphaAR, this polarization occurs after initial random insertion of the alphaAR into both apical and basolateral surfaces followed by selective retention on the lateral subdomain (ton the apical surface is 15-30 min; ton the basolateral surface is 8-10 h). The alphaAR also is enriched on the basolateral surface at steady-state and, like the alphaAR, is directly delivered there. Morphological evaluation of the epitope-tagged alphaAR, alphaAR, and alphaAR subtypes by laser confocal microscopy not only corroborated the biochemically-defined basolateral localization of all three alpha(2)AR subtypes but also revealed that the alphaAR uniquely exists in an intracellular compartment(s) as well. Immunofluorescence due to intracellular alphaAR partially overlaps that due to calnexin, a marker for endoplasmic reticulum, as well as that due to mannosidase II, a marker for the trans-Golgi network. Taken together, the present findings demonstrate that the alphaAR, alphaAR, and alphaAR subtypes, which possess highly homologous structures and ultimately achieve similar polarization to the lateral surface of MDCK II cells, nonetheless manifest distinct trafficking itineraries.


INTRODUCTION

alpha(2)-Adrenergic receptors (alpha(2)ARs) (^1)belong to a superfamily of G-protein-coupled receptors that have seven predicted transmembrane spanning regions. The three alpha(2)AR subtypes, called alpha, alpha, and alphaAR, all couple to the G-proteins of the G and G class and mediate a variety of physiological responses via pertussis toxin-sensitive signal transduction pathways, including inhibition of adenylyl cyclase, activation of receptor-operated K channels, and suppression of voltage-gated Ca channels(1) .

The alpha(2)AR has been demonstrated in the kidney of several mammalian species(2, 3) . Although these receptors are concentrated in the proximal tubular segment of the nephron, they also are found in the glomerulus, thin descending limb of Henle's loop and cortical collecting duct. The physiological function of the alpha(2)AR in the proximal tubule is to increase Na reabsorption and proton secretion via the modulation of Na/H exchange(2, 4) . The precise physiological role for each of the alpha(2)AR subtypes is not yet defined.

The expression of multiple alpha(2)AR subtypes in the kidney (5) and the effects of adrenergic agents on renal physiology encouraged us to explore one determinant of receptor-mediated function, namely the precise localization of the receptor molecules in the plasma membrane of renal epithelial cells. Renal epithelial cells are polarized both morphologically and functionally into at least two distinct compartments: apical and basolateral. Both radioligand binding studies and renal microperfusion experiments are consistent with the interpretation that alpha(2)ARs are present primarily on the basolateral membrane domain of renal epithelial cells in vivo(6, 7) . How this localization is achieved for the alpha(2)AR, or for any G-protein-coupled receptor, is only beginning to be revealed.

Recent studies from our laboratory have examined the targeting and retention of wild-type and epitope-tagged alphaAR in cultured Madin-Darby canine kidney (MDCK II) cells, a model system that achieves morphological and functional polarity following culture on Transwell filters(8) . Surface biotinylation strategies demonstrated that 85-90% of the wild-type alphaAR population is localized on the basolateral surface of MDCK II cells, in a manner analogous to the localization of this receptor in vivo. Furthermore, immunochemical detection of the alphaAR, based on the recognition of an artificial epitope tag introduced by mutagenesis into the amino terminus of the receptor, has revealed that the alphaAR is not randomly distributed in the basolateral surface but is highly enriched on the lateral subdomain of polarized MDCK II cells. This localization is achieved by direct delivery to this surface, based on findings from metabolic labeling studies. Extensive mutational analysis of the alphaAR to reveal structural regions that confer direct alphaAR delivery to the basolateral surface suggests that basolateral targeting of alphaAR does not rely on amino-terminal glycosylation, carboxyl-terminal acylation, nor amino acid sequences within the third cytoplasmic loop and the carboxyl-terminal tail(9) . These findings are consistent with the interpretation that sequences in or near the lipid bilayer are involved in the delivery of the alphaAR to the basolateral surface. In contrast, the deletion of the predicted third cytoplasmic loop of the alphaAR significantly decreases its half-life on the epithelial cell surface, suggesting that this structural region of alphaAR may participate in mechanisms that stabilize the receptor on the lateral subdomain.

The existence of three subtypes of alpha(2)AR that possess regions of structural similarity and diversity provides natural reagents to further understand the structural regions of G-protein-coupled receptors that confer information for targeting and stabilization in polarized cells. The three alpha(2)AR subtypes (alphaAR, alphaAR, and alphaAR) can be distinguished not only by differences in pharmacological specificity but also by differences in their primary amino acid sequences. Although sequences in the seven transmembrane-spanning domains are highly conserved among the alpha(2)AR subtypes, the large third cytoplasmic loop and the amino and carboxyl termini of the alpha(2)AR subtypes demonstrate significant sequence dissimilarity(10, 11, 12, 13) . In addition, the post-translational modification of these three receptors is quite different. For example, the alphaAR has sequences (10, 11) which confer amino-terminal glycosylation (14) and carboxyl-terminal acylation(15) . In contrast, the alphaAR is not glycosylated(13, 14, 16) , but its carboxyl terminus does contain the sequences appropriate for acylation, whereas the alphaAR does not contain acylation signals but does possess glycosylation signals in the amino terminus (12) .

The structural differences among the alpha(2)AR subtypes led us to explore the possibility of a different targeting mechanism for each subtype, possibly resulting in differential receptor subtype localization. The present findings demonstrate that although the alpha, alpha, and alphaAR subtypes ultimately achieve basolateral localization at steady-state, they do so by different molecular mechanisms. Thus, the alphaAR shares the direct basolateral delivery pathway characteristic of the alphaAR, but is not exclusively localized on the cell surface at steady-state. The alphaAR, which achieves almost complete basolateral localization at steady-state, does so following apparent random delivery to both surfaces and prolonged retention on the basolateral surface.


EXPERIMENTAL PROCEDURES

Materials

The alphaAR (RNG) and alphaAR (RG10) cDNAs were kindly provided by Drs. Kevin Lynch (University of Virginia) and Stephen Lanier (University of South Carolina), respectively. The protein A-purified 12CA5 monoclonal antibody was obtained from the Berkley Antibody Co. (BABCO), Affi-Gel 10 and Affi-Gel 15 were purchased from Bio-Rad, and the Cy3-conjugated donkey anti-mouse IgG was from Jackson Immunochemicals. The anti-mannosidase II polyclonal antibody (17) was a kind gift from Drs. Marilyn Farquhar (University of California in San Diego) and Kelley Moremen (University of Georgia). The anti-calnexin polyclonal antibody (18) was purchased from StressGen Biotechnologies Corp. [^3H]Rauwolscine (80 Ci/mmol), [S]EXPRESS protein labeling mixture (1200 Ci/mmol), and [^3H]methoxyinulin (125.6 mCi/g) were from DuPont NEN. The precursor 17alpha-hydroxy-20alpha-yohimban-16beta-(N-4-aminophenethyl)-carboxamide (Rau-AzPEC) was a kind gift from Dr. Lanier and the radioiodinated azido derivative, [I]Rau-AzPEC, was synthesized in our laboratory as described by Lanier et al.(19) . Phentolamine was a gift from CIBA Pharmaceutical Co. Biotin LC-Hydrazide, sulfo-NHS-biotin, and streptavidin-agarose were purchased from Pierce. Protein A-agarose was obtained from Vector Laboratories. Dulbecco's modified Eagle's medium was prepared by the Cell Culture Core facility sponsored by the Diabetes Research and Training Center at Vanderbilt University Medical Center. Fetal calf serum was purchased from Sigma. Transwell plates (0.4 µm pore size) were obtained from Costar. Sep-Pak columns were from Millipore Corp. The Sequenase Kit was obtained from U. S. Biochemical Corp. All other chemicals utilized were reagent grade.

Construction of Epitope-tagged alphaAR and alphaAR Receptor Structures

The alpha and alphaARs were epitope-tagged at either the amino or carboxyl terminus. The hemagglutinin TAG was introduced into the amino termini of the alpha and alphaARs (termed TAG-alphaAR and TAG-alphaAR) by site-directed mutagenesis in pBluescript II vector after initial isolation of single-stranded DNA. The hemagglutinin epitope TAG is encoded by the first 9 of the 11 added amino acids (YPYDVPDYALA). Mutants containing the TAG sequence were confirmed by dideoxy-DNA sequencing using T7 DNA polymerase and [alpha-S]dATP. Appropriate mutant structures were then subcloned into the polylinker region of pCMV4 mammalian expression vector (8) and the correct DNA sequence was confirmed again.

Introduction of the epitope tag into the carboxyl termini of the alpha and alphaARs (termed alpha-TAG-AR and alpha-TAG-AR) was achieved using polymerase chain reaction (PCR)-based mutagenesis. The alphaAR 5` oligonucleotide (24-mer) was 5`-GGCTACTGCAACAGCTCTTTGAAC. The alphaAR 3` oligonucleotide containing the hemagglutinin TAG sequence, the stop codon, and an EcoRV restriction site (82-mer with 24 bases annealing) was 5`-CTAGGATATCTCAACGAGGAGCTAGCGCGTAGTCAGGAACGTCGTAAGGATAGCTAGCCCAGCCAGTCTGGGTCCACGGCCG. The alphaAR 5` oligonucleotide (24-mer) was 5`-CGCATCTACCGCGTGGCCAAGCTG. The alphaAR 3` oligonucleotide containing the hemagglutinin TAG sequence, the stop codon, and a SmaI restriction site (82-mer with 24 bases annealing) was 5`-CTAGCCCGGGTCAACGAGGAGCTAGCGCGTAGTCAGGAACGTCGTAAGGATAGCTAGCCTGCCTGAAGCCCCTTCTCCTCCT. The 82-mer oligonucleotides were purified on a 9% PAGE, the appropriate bands were excised, eluted, and passed over C18 Sep-Pak columns. The 24-mer oligonucleotides were purified on C18 Sep-Pak columns. The PCR reactions were done at high denaturing temperature (98 °C) in the presence of 5% dimethyl sulfoxide following a ``hot start'' in the absence of DNA polymerase at 90 °C for 30 min. Thermal stable VENT DNA polymerase was required for these PCR reactions due to a high GC content of the DNA sequences encoding the predicted third cytoplasmic loop of the alpha(2)AR subtypes. In case of each alpha(2)AR subtype, double-stranded DNA template (5 ng) was used with the respective oligonucleotides at a final concentration of 0.5 µM. The incubation also contained 0.25 mM dNTPs, 1 times VENT DNA polymerase buffer, and 1 unit of VENT DNA polymerase in a final volume of 100 µl with a top layer of mineral oil. The PCR conditions were as follows: denaturing at 98 °C for 1 min, annealing at 68 °C for 1 min, extension at 72 °C for 2 min for 35 cycles, followed by a 10-min extension at 72 °C and storage at 4 °C. Obtained PCR products were purified on agarose gels and digested with the appropriate restriction enzymes; alpha-TAG-AR PCR product (167 bp) was cut with EcoRV and BstBI, and alpha-TAG-AR PCR product (744 bp) was digested with SmaI and MluI. Obtained alpha-TAG-AR (99 bp) and alpha-TAG-AR (740 bp) fragments were purified on agarose gels and subcloned into the pCMV4-alphaAR plasmid (in place of the EcoRV-BstBI fragment encoding wild type sequence) and pCMV4-alphaAR expression plasmid (instead of the wild type SmaI-MluI fragment), respectively.

The sequence of all of these mutant constructs was confirmed by double-stranded dideoxy-DNA sequencing using T7 DNA polymerase and [alpha-S]dATP. Transient transfection of COS M6 cells (100-mm dish plated at 1 times 10^6 cells/dish) with 10 µg of each expression plasmid utilizing the DEAE-dextran method (9) was employed to assess the level of receptor expression using [^3H]yohimbine binding as well as to examine the detectability of the epitope TAG by immunocytochemistry prior to utilization of the DNA to develop permanent transformants.

Creation of Permanent Clonal MDCK II Cell Lines

Permanent clonal cell lines were developed using the CaPO(4) precipitation method, as described previously(8) . Briefly, 20 µg of the expression plasmid were co-transfected with 2 µg of pRSVneo into 1 times 10^6 MDCK II cells. Colonies expressing the neomycin resistance gene were selected with the neomycin analog G418 (500 active µg/ml), isolated, and screened for the expression of alpha(2)AR by measuring the binding of the alpha(2)AR antagonist [^3H]rauwolscine and the alpha(2)AR agonist p- [I]iodoclonidine.

Cell Cultures

Madin-Darby canine kidney (MDCK II) cells, kindly provided by Dr. Enrique Rodriquez-Boulan (Cornell University), were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin at 37 °C, 5% CO(2). MDCK II cells were plated on polycarbonate membrane filters (Transwell) at a density of 1 times 10^6 cells/24.5-mm Transwell and maintained in culture for 7-8 days, changing medium every day, at which time the cells achieved a morphologically and functionally polarized phenotype(8) . In the present studies, we examined multiple MDCK II clonal cell lines as summarized in Table 1.



Leak Assay

Leak assays were performed to determine whether the MDCK II cells developed tight junctions, and served as an indication of their integrity as a monolayer on Transwell filters. [^3H]Methoxyinulin was added to the growth medium in the apical compartment and the leak of this radioligand from the apical to basolateral compartment was assessed after a 1-h incubation at 37 °C. A typical [^3H]methoxyinulin leak ranged from 1 to 2%. Transwells exhibiting leaks greater than 2% were excluded from study.

Receptor Localization at Steady-state

a) Biochemical Approach Utilizing the Surface Biotinylation Strategy

The distribution of the alpha(2)AR on the apical versus the basolateral membrane domain in MDCK II permanent clonal cell lines can be quantitated using surface biotinylation strategies as described previously(8, 9) . Briefly, glycoproteins (which include the alphaAR and alphaAR) on either the apical or the basolateral surface of MDCK II clones grown on Transwell cell culture system were covalently modified with biotin LC-hydrazide, while primary amines of the non-glycosylated alphaAR were covalently labeled with sulfo-NHS-biotin. Following membrane preparation, alpha(2)ARs were identified by covalent modification with the photoactivatable alpha(2)AR-selective ligand [I]Rau-AzPEC for 1 h at 15 °C in the dark. Photolabeling not attributable to receptor binding was determined in parallel incubations carried out in the presence of 10 µM phentolamine, an alpha-adrenergic antagonist. The photoaffinity-labeled receptor was then extracted with RIPA buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 0.5 mM EDTA, 1% Nonidet P-40, 0.5% deoxycholate, and 0.1% SDS) and streptavidin-agarose chromatography was employed to isolate the previously biotinylated molecules. The fraction of the biotinylated alpha(2)AR present on the apical versus the basolateral membrane domain was determined following SDS-PAGE, autoradiography, and cutting and counting of radiolabeled bands corresponding to the migration of the alphaAR, alphaAR, and alphaAR.

b) Morphological Approach Employing Immunocytochemistry

Clonal cell lines grown on polycarbonate filters were excised from the Transwell support, rinsed with phosphate-buffered saline (PBS), and fixed for 30 min at 22 °C (room temperature) with 4% (v/v) paraformaldehyde in PBS (alphaAR and alphaAR) or 15 min with 2% (v/v) paraformaldehyde in PBS (alphaAR). Cells were rinsed twice with PBS, incubated in 50 mM NH(4)Cl solution in PBS for 15 min to quench the fixative, and then permeabilized with 0.2% Triton X-100 in PBS for 15 min at room temperature. Potential sites for nonspecific antibody binding were blocked by a 15-min incubation with 1% BSA, 0.2% Triton X-100, 0.04% sodium azide in PBS at room temperature. The primary antibody, affinity-purified (see below) 12CA5 mouse monoclonal antibody directed against the hemagglutinin epitope, was diluted 1:25 in 1% BSA, 0.2% Triton X-100, 0.04% sodium azide in PBS and incubated with the sample for 1 h at room temperature. This was followed by four 15-min washes with 0.2% Triton X-100 in PBS and a 1-h incubation with a secondary Cy3-conjugated donkey anti-mouse IgG (1:100 dilution in 1% BSA, 0.2% Triton X-100, 0.04% sodium azide in PBS). The cells were washed as before with PBS containing 0.2% Triton X-100 and mounted on glass microscope slides with Aqua Polymount. The results were analyzed either on a Leitz Fluorescent Microscope using a 40 times oil immersion lens or on a Zeiss laser confocal microscope.

Immunological co-localization studies were done essentially as described above, although expanded by the additional application of another primary and secondary antibody. Incubation with 1:400 dilution of an anti-calnexin rabbit polyclonal antibody (used as a marker for the endoplasmic reticulum(18) ), or a 1:1000 dilution of anti-mannosidase II rabbit polyclonal antibody (used to detect trans-Golgi network(17) ) in 1% BSA, 0.2% Triton X-100, 0.04% sodium azide followed the initial detection of the alphaAR with 12CA5 antibody and FITC (1:60 dilution) or Cy3 (1:100 dilution)-conjugated donkey anti-mouse IgG. The anti-calnexin or anti-mannosidase II primary antibodies were incubated with the sample for 1 h at room temperature, followed by four 15-min washes with 0.2% Triton X-100 in PBS and a 1-h incubation with a secondary donkey anti-rabbit FITC (1:60 dilution) or Cy3 (1:200 dilution)-conjugated IgG in 1% BSA, 0.2% Triton X-100, 0.04% sodium azide in PBS. The cells were then washed four times for 15 min with PBS, 0.2% Triton X-100, mounted, and analyzed as described above.

Since the initial immunoanalysis of alphaAR localization in MDCK II cells revealed a significantly lower level of fluorescent signal as compared to the alphaAR, we generated additional alphaAR and alphaAR DNA constructs and clonal cell lines. We were concerned that the epitope tag of the TAG-alphaAR was not easily accessible to 12CA5 antibody because this subtype has an unusually high alanine content (17 alanine residues) in its amino-terminal region, potentially leading to the formation of helices. Consequently, we deleted the 3`-untranslated regions (280 bp in TAG-alphaAR and approximately 500 bp in TAG-alphaAR) in order to increase receptor expression (20) and simultaneously inserted the hemagglutinin epitope tag into carboxyl termini of both subtypes to make the epitope more accessible to the antibody and also to ascertain that the localization was independent of the epitope-insertion site.

Purification of the 12CA5 Monoclonal Antibody on Activated Affi-Gel 10 and Affi-Gel 15

The Protein A-purified 12CA5 antibody obtained commercially manifested variable background staining in parental MDCK II cells. Particularly for evaluation of the localization of the alphaAR subtype, which was reported previously to possess intracellular as well as surface localization(21) , we needed to eliminate non-epitope-dependent fluorescence in MDCK II cells incubated with 12CA5 antibody directed against the 9 amino acid epitope tag. Consequently, we employed a previously recommended strategy to deplete antibody of background-interacting contaminants before examining epitope expression in heterologous cells(22) . The rationale is to adsorb proteins in total lysates of MDCK II cells to Affi-Gel 10 and Affi-Gel 15, and then use these resins to deplete the commercial 12CA5 preparation of nonspecific adsorbents. Lysates of parental MDCK II cells were prepared in the following manner. It was determined in advance how many 100-mm dishes grown to confluence were needed to obtain approximately 50 mg of MDCK II lysate protein. This number of dishes were washed in Affi-Gel buffers appropriate for subsequent coupling to Affi-Gels: 0.1 M MOPS, pH 7.5, 80 mM CaCl(2) was used for Affi-Gel 10, while 0.1 M MOPS, pH 7.5, 0.3 M NaCl was used for Affi-Gel 15. Cells were harvested in the smallest possible volume of buffer (such that the total volume did not exceed 1 ml) using a rubber policeman, collected in 1.5-ml Eppendorf tubes, and homogenized by 20 up and down strokes using a 1-ml syringe with a 20-gauge needle. Affi-Gel 10 and Affi-Gel 15 (1 ml of each gel) were prewashed three times in separate Eppendorf tubes with ice-cold 10 mM sodium acetate solution, pH 4.5, after which the whole cell lysate preparations were added onto the appropriate Affi-Gel. The cell lysate-Affi-Gel coupling reactions were rotated for 4 h at 4 °C, followed by multiple washes of the conjugated Affi-Gel with the appropriate coupling buffer on a 50-micron mesh column. Affi-Gels were determined to be free of reactants by measurements of OD. The Affi-Gels free of unbound lysate particles were collected in clean 1.5-ml Eppendorf tubes and incubated in the presence of 1 M ethanolamine-HCl, pH 8.0, for 1 h at 4 °C in order to block any reactive esters on the Affi-Gels. Each Affi-Gel was then washed again with the appropriate coupling buffer. Following the third wash, an aliquot of 12CA5 antibody was added sequentially to Affi-Gel 10 and Affi-Gel 15 and allowed to rotate 4 h with each of the Affi-Gels at 4 °C. Typically 1 ml of 12CA5 antibody (10 mg/ml) was added to 500 µl of Affi-Gel 10 and then to 500 µl of Affi-Gel 15. The final supernatant, comprising the purified 12CA5 antibody, was aliquoted and stored at -80 °C. Multiple independent purifications of 12CA5 antibody have indicated that there is no loss of the component of the 12CA5 that recognizes the HA epitope using this procedure, but there is a dramatic decrease in the amount of nonspecific, background staining.

Assessment of the Delivery of alpha(2)AR Subtypes to the Apical versus Basolateral Cell Surfaces

Permanent clonal cell lines grown in Transwell cell culture wells were metabolically labeled with [S]cysteine/methionine ([S]EXPRESS) for various periods of time, as described previously in detail(8, 9) . Upon completion of the metabolic labeling phase (``pulse''), proteins on either the apical or the basolateral membrane were covalently modified with biotin LC-hydrazide or sulfo-NHS-biotin. Detergent-solubilized alpha(2)ARs were then immunoisolated using the 12CA5 antibody and the fraction of the alpha(2)AR that had been biotinylated on a particular surface was isolated by subsequent streptavidin-agarose chromatography.

Determination of Receptor Half-life on the Apical versus the Basolateral Cell Surface

MDCK II clones grown on Transwell supports were metabolically labeled (``pulsed'') with 150 µCi/well of [S]cysteine/methionine for the time periods given in individual figure legends and then incubated with complete Dulbecco's modified Eagle's medium supplemented with 1 mM cysteine and 1 mM methionine (``chased'') for various periods of time at 37 °C. Determination of the metabolically labeled alpha(2)AR present on either the apical or the basolateral surface at each time point relied on sequential biotinylation, detergent extraction, immunoisolation, and streptavidin-agarose chromatography, as described in detail previously by Keefer et al.(8) . SDS-PAGE was utilized to resolve the radiolabeled proteins. The quantity of S-labeled alpha(2)AR remaining on either the apical or the basolateral surface after each ``chase'' period was quantified by cutting and counting the regions of the gel corresponding to the migration of a particular alpha(2)AR subtype detected on the biotinylated surface.


RESULTS AND DISCUSSION

In the present studies, we examined whether the three subtypes of alpha(2)AR are differentially localized in MDCK II cells and whether the modes of receptor delivery to the cell surface or their half-lives on the membrane after surface delivery differ among the three subtypes.

All Three alpha(2)AR Subtypes Achieve Basolateral Localization in MDCK II Cells at Steady-state

Steady-state localization of each alpha(2)AR subtype was determined using surface biotinylation strategies in multiple permanent clonal cell lines grown in Transwell culture. The alpha(2)ARs were identified using photoaffinity labeling with [I]Rau-AzPEC. The specificity of labeling was documented by comparing the profile of radiolabeled bands on SDS-PAGE incubated with [I]Rau-AzPEC in the absence or presence of the alpha-adrenergic antagonist, phentolamine. As shown in Fig. 1, the alphaAR (Fig. 1A) and alphaAR (Fig. 1C) subtypes migrate just above the 66-kDa molecular mass marker, consistent with the glycosylation of these 442 (alphaAR) and 461 (alphaAR) amino acid receptors. In contrast, the alphaAR subtype migrates at approximately 45 kDa on SDS-PAGE, as expected for this non-glycosylated 453 amino acid receptor subtype(14, 16) . Quantitation of the fraction of each alpha(2)AR subtype that is biotinylated on the basolateral versus apical surface indicates that 91% of the WT-alphaAR, 89% of the TAG-alphaAR, 97% of the WT-alphaAR, 85% of the TAG-alphaAR, 95% of the WT-alphaAR, and 92% of the TAG-alphaAR are localized on the basolateral surface at steady-state. Furthermore, the fraction of alphaAR or alphaAR enriched on the basolateral surface was not altered quantitatively if the epitope tag was introduced into the amino or carboxyl terminus of the receptor. Comparable amounts of the radiolabeled receptor are detected in detergent-solubilized extracts obtained from Transwell cultures biotinylated on either the apical or basolateral surface prior to streptavidin-agarose chromatography ((8) ; data not shown). Thus, the overwhelmingly greater basolateral signal detected following streptavidin-agarose chromatography of the extracts from biotinylated cells is a true reflection of alpha(2)AR enrichment on the basolateral surface of MDCK II cells. The finding that introduction of the epitope tag did not alter the apparent localization of any of the alpha(2)AR subtypes meant that these epitope-tagged structures could be exploited in subsequent immunochemical and metabolic labeling studies and yet faithfully represent the fate of the wild-type alpha(2)AR subtype structure.


Figure 1: Basolateral localization of all three alpha(2)AR subtypes in MDCK II cells at steady-state. Autoradiograms presented in this figure were obtained using the following permanent MDCK II clonal cell lines expressing either the wild-type or the epitope-tagged alpha(2)AR subtypes: WT-alphaAR 12 and TAG-alphaAR 3 (both shown in panel A); WT-alphaAR 67 and TAG-alphaAR 122 (both shown in panel B); WT-alphaAR 90 and TAG-alphaAR 11 (both shown in panel C). Polarized MDCK II cells from three 24-mm Transwell filters were biotinylated on either the apical or the basolateral surface and the alpha(2)ARs were photoaffinity labeled with [I]Rau-AzPEC in the absence or presence of the alpha-AR antagonist phentolamine. We have noted that significantly less total receptor in the preparation of alphaAR was required to obtain a sufficient signal comparable to that of alphaAR and alphaAR subtypes. This observation would suggest that the alphaAR has a greater affinity for the iodinated photolabel than the other alpha(2)AR subtypes. Following detergent extraction of the photolabeled preparations and subsequent streptavidin-agarose chromatography, the eluates from the streptavidin-agarose were analyzed on 7-20% gradient SDS-PAGE and subsequently subjected to autoradiography. Autoradiograms shown represent one of at least five independent experiments for each receptor subtype, where comparable findings were obtained. To quantitate the fraction of the alpha(2)AR subtype localized apically or basolaterally, the gel regions corresponding to migration of the alpha(2)AR subtypes were cut and counted in a -counter, as described under ``Experimental Procedures.''



Since surface biotinylation strategies only reveal the fraction of the receptor population at either the apical or basolateral surface, we also employed immunocytochemical methods to evaluate the surface as well as possible intracellular localization of each of the alpha(2)AR subtypes within MDCK II cells. MDCK II clones were grown in Transwell culture and immunostained using the Affi-Gel-purified 12CA5 antibody directed against the epitope tag (see ``Experimental Procedures''). The surface staining pattern of the three alpha(2)AR subtypes corroborates the basolateral localization revealed using surface biotinylation strategies. For the alphaAR and alphaAR, the immunofluorescence was detected exclusively on the lateral subdomain of MDCK II cells (Fig. 2). The alphaAR, however, is localized not only on the lateral subdomain, but also in intracellular compartments. Our findings in MDCK II cells resemble previous reports of both surface and intracellular localization of the alphaAR when expressed in COS-7 and HEK-293 renal cell lines(21) . This bimodal surface and intracellular localization of the alphaAR, unique among the alpha(2)AR subtypes, must represent a property of the alphaAR structure per se, since the same 12CA5 antibody preparation was used to immunologically localize all three subtypes of the alpha(2)AR. Furthermore, as mentioned above, introduction of the epitope tag into the amino- versus the carboxyl-terminal domains of the alphaAR did not alter its steady-state distribution, assessed using either biochemical or morphological strategies. Finally, we also examined several independent clonal cell lines (see Table 1), and found that the relative distribution of alpha(2)AR for all subtypes was unmodified over the range of 2 to 25 pmol of alpha(2)AR/mg of protein. Thus, we are confident that the receptor distribution shown in Fig. 2represents properties of the structures of the varying alpha(2)AR subtypes.


Figure 2: Immunological localization of the three alpha(2)AR subtypes in polarized MDCK II cells using 12CA5 antibody. MDCK II clones expressing the epitope-tagged alpha(2)AR subtypes (TAG-alphaAR 3, TAG-alphaAR 122, and TAG-alphaAR 11 clonal cell lines) were polarized on the Transwell system, fixed, and immunostained as described under ``Experimental Procedures.'' The localization of the hemagglutinin epitope tag determined by immunochemical strategies described in detail under ``Experimental Procedures'' was analyzed on a Zeiss laser confocal microscope. Localization of the epitope-tagged alphaAR, alphaAR, and alphaAR in the XY plane is presented in the lower panel of each image set. Z scans shown in the upper panel of each image set show a laser-sectioned side view of MDCK II cells expressing each of the three receptor subtypes. The yellow line across each XY plane represents the exact site where the cells were sectioned from top to bottom with the laser beam to create the Z scan.



Comparison of the Localization of Intracellular alphaAR with Calnexin and Mannosidase II

In order to explore the cellular compartment(s) where the intracellularly-localized alphaAR might be expressed, we compared the immunological localization of the alphaAR with that of calnexin(18) , a marker for the endoplasmic reticulum, and mannosidase II, a marker for the trans-Golgi network(17) . Fig. 3compares the localization of alphaAR (Panels A and D) with mannosidase II (Panels B and E). Panels C and F in Fig. 3examine the co-localization (yellow color) of alphaAR (green color due to the FITC-conjugated secondary antibody) and mannosidase II (red color due to the Cy3-conjugated secondary antibody). Laser sectioning in the Z plane is most informative in revealing the extent, or lack thereof, of alphaAR co-localization with markers for the endoplasmic reticulum and trans-Golgi network. As shown in Fig. 3C, the staining for the intracellular alphaAR completely overlaps that observed for mannosidase II, whereas in other cross-sections (e.g.Fig. 3F) the immunofluorescence of the intracellular alphaAR expands apically from the trans-Golgi network, which is defined by mannosidase II staining. Similarly, the profile of the intracellular alphaAR immunofluorescence partially overlaps that for calnexin, but also occupies cellular space oriented apically from endoplasmic reticulum (Fig. 3I), as defined by calnexin staining. Taken together, the findings in Fig. 3(C, F, and I) suggest either that the intracellular alphaAR is distributed throughout the endoplasmic reticulum and trans-Golgi network, or is localized to a unique subcellular compartment that is characterized by an immunofluorescence profile that partially overlaps both calnexin and mannosidase II staining.


Figure 3: Immunological co-localization of the alphaAR subtype with markers for endoplasmic reticulum (calnexin) and trans-Golgi network (mannosidase II). MDCK II clones permanently expressing the HA epitope-tagged alphaAR subtype (TAG-alphaAR 11 and alpha-TAG-AR 77) were polarized on Transwells, fixed, and immunostained as described under ``Experimental Procedures.'' The 12CA5 primary mouse monoclonal antibody was detected by a secondary donkey anti-mouse FITC (panels A and D) or Cy3 (G)-conjugated IgG. The calnexin or mannosidase II rabbit polyclonal antibodies were detected with a secondary donkey anti-rabbit Cy3 (panels B and E) or FITC (panel H)-conjugated IgG. Panel I shows a co-localization of 12CA5 and anti-calnexin antibody staining, while panels C and F show a co-localization of 12CA5 and anti-mannosidase II antibody staining. In panels C, F, and I, the 12CA5 incubation was followed by a secondary donkey anti-mouse FITC (panels C and F) or Cy3 (panel I)-conjugated IgG; subsequently a second primary antibody (anti-Calnexin, in panel I, or anti-mannosidase II in panels C and F) was added for 1 h, followed by a secondary donkey anti-rabbit FITC (panel I) or Cy3 (panels C and F)-conjugated IgG. The yellow line across the XY scan indicates the plane of sectioning of the Z scan, as described in the legend to Fig. 2.



The alphaAR, Like alphaAR, Is Delivered Directly to the Basolateral Membrane of MDCK II Cells, While the alphaAR Is Initially Randomly Inserted into Both Apical and Basolateral Surfaces

Our next goal was to determine if all three subtypes of alpha(2)AR are directly delivered to the basolateral surface of MDCK II cells, where they predominantly reside at steady-state, or alternatively, if alpha(2)AR subtypes achieve this steady-state localization via distinct mechanisms. Delivery of the alpha(2)AR subtypes was examined by metabolic labeling of nascent receptors, followed by biotinylation on the apical or basolateral cell surface, immunoisolation using the anti-epitope tag antibody, and quantitation of the fraction of alpha(2)AR biotinylated on a particular surface following streptavidin-agarose chromatography.

Metabolic labeling studies require the epitope-tagged receptor as a means to identify and isolate the alpha(2)AR among the other radiolabeled proteins. Thus, for these studies we were restricted to using clonal cell lines permanently expressing the epitope-tagged versions of alpha(2)AR subtypes to study receptor delivery to the cell surface. Fortunately, all of our steady-state data comparing the localization of photoaffinity-labeled alpha(2)AR indicate that introduction of the epitope tag does not influence the localization of any of the alpha(2)AR subtypes (cf. Fig. 1). It was of interest, however, that we were able to immunoisolate the alphaAR subtype only when the epitope tag was inserted into the carboxyl terminus; perhaps the alanine-rich sequence in the amino terminus of the alphaAR rendered the tag inaccessible to the 12CA5 antibody when inserted in the amino terminus.

Fig. 4examines the delivery of all three alpha(2)AR subtypes in MDCK II cells. In all cases, we are confident that the radiolabeled band identified as alpha, alpha, or alphaAR represents the particular subtype under study, because of its comigration with photoaffinity-labeled receptor and its absence when comparable metabolic labeling studies are performed in parental MDCK II cells lacking expression of any of these subtypes. The band migrating just above the 66-kDa molecular mass marker on SDS-PAGE is interpreted to represent the alphaAR (Fig. 4A) and alphaAR (Fig. 4C) subtype. Newly synthesized alphaARs (Fig. 4C), like the alphaAR (Fig. 4A), appear virtually exclusively on the basolateral surface after each labeling time point tested. These data are consistent with the interpretation that both the alphaAR and alphaAR subtypes are delivered directly to the basolateral surface. In contrast, the alphaAR shows a fundamentally different targeting pattern when compared to the alphaAR and alphaAR subtypes. As shown in Fig. 4B, the 45-kDa alphaAR is initially randomly inserted into both apical and basolateral surfaces, where it is first detectable 30 min after initiation of metabolic labeling. This random expression on both the apical and basolateral surfaces also is repeatedly observed 45 min after pulse labeling of this receptor subtype. However, 60 min after the initiation of metabolic labeling, the majority of the alphaAR is found on the basolateral membrane. The data shown in Fig. 4B are from one experiment repeated 6 times with comparable outcome. The alphaAR subtype delivery was assessed using receptor structures where the epitope tag was introduced either into the amino or carboxyl terminus, and the indistinguishable results obtained for either epitope-tagged structure suggest that position of epitope tag does not influence the apparent random delivery of the alphaAR in MDCK II cells.


Figure 4: Direct versus random cell surface delivery of different subtypes of the alpha(2)AR in MDCK II cells. The following MDCK II clones permanently expressing the epitope-tagged alpha(2)AR subtypes were used to obtain the shown autoradiograms: TAG-alphaAR 3 (A), TAG-alphaAR 122 (B), and alpha-TAG-AR 28 (C). Polarized MDCK II clonal cell lines grown on three or four 24-mm Transwell filters (depending on the receptor expression level) for 7 days were metabolically labeled with 150 µCi of [S]cysteine/methionine in 150 µl of medium at 37 °C, 5% CO(2) for the indicated periods of time and then biotinylated on either the apical or the basolateral surface. The alpha(2)AR delivered to the biotinylated surface were isolated via sequential Protein A and streptavidin-agarose chromatography, as described under ``Experimental Procedures.'' Eluates from the streptavidin-agarose resin were analyzed by 7-20% gradient SDS-PAGE and subsequent autoradiography. Shown here are representative autoradiograms of at least three independent experiments for each receptor subtype (for the alphaAR, this experiment was repeated 6 times), which yielded comparable findings.



The alphaAR Subtype Is Selectively Retained on the Basolateral Surface

One possible scenario that could explain the initial uniform distribution of the alphaAR on apical and basolateral surfaces followed by enrichment on the basolateral surface would involve selective retention of the alphaAR in the basolateral, but not in the apical, domain. To determine if the alphaAR was selectively retained on the basolateral surface, we directly examined the half-life of the alphaAR on both the apical and basolateral surfaces of MDCK II cells. Cells grown in Transwell culture were metabolically labeled with []cysteine/methionine, and then chased with cysteine and methionine-enriched medium for various time periods before evaluating alphaAR surface distribution (see ``Experimental Procedures''). Using this experimental approach the alphaAR was observed to possess a half-life on the apical surface of 15-30 min (Fig. 5A) but a half-life on the basolateral surface of 8-10 h (Fig. 5B). At present, we cannot determine whether or not the alphaAR, after removal from the apical surface, is redirected to the basolateral surface or, alternatively, is internalized and degraded. However, the differential stability of alphaAR on the apical versus the basolateral membrane explains the observation that, at steady-state, the alphaAR is localized almost exclusively on the basolateral surface. Furthermore, this finding suggests that each membrane domain has a unique mechanism for protein retention and, moreover, that the apical retention mechanism for the alphaAR is less efficient.


Figure 5: Differential retention of the alphaAR subtype on the apical versus the basolateral surface of MDCK II cells. MDCK II cells permanently expressing the alpha-TAG-AR clone 42 (A) or TAG-alphaAR clone 122 (B) were metabolically labeled with 150 µCi of [S]cysteine/methionine in 150 µl of medium at 37 °C, 5% CO(2) for 30 (A) or 60 (B) min, then chased in medium supplemented with 1 mM methionine and 1 mM cysteine for the indicated time periods. After completion of the chase period, cells were biotinylated on either the apical (A) or the basolateral (B) surface with NHS-biotin. Subsequently, the alphaAR was isolated via sequential protein A-agarose and streptavidin-agarose chromatography, and resolved on SDS-PAGE. The upper panels of A and B show representative autoradiograms. Upon excision and counting gel bands that correspond to the alphaAR, the percentage of radioactivity present in each receptor band was plotted as a function of time (radioactivity present in t(0) (time = 0) band was ascribed as 100%). The means ± S.E. of radioactivity present in alphaAR corresponding gel bands averaged from n = 7 (A) and n = 3 (B) are shown in the lower panels of A and B. The calculated half-life of the alphaAR on the apical surface was 15-30 min, whereas the calculated half-life of the alphaAR on the basolateral surface was 8-10 h.



Fig. 6demonstrates that the alphaAR, alphaAR, and alphaAR have comparable half-lives on the basolateral surface. Previous data from our laboratory suggest, at least for the alphaAR, that receptor retention involves protein-protein interactions involving endofacial domains of the receptor, since deletion of the third cytoplasmic loop of the alphaAR measurably accelerates receptor turnover on the basolateral surface(9) . The similar half-life of the alphaAR, alphaAR, and alphaAR subtypes on the basolateral surface suggests that similar tethering mechanisms may exist for all three structures despite the fact that the endofacial third loop sequences of these three alpha(2)AR subtypes are quite distinct. Perhaps these alpha(2)AR subtypes, when they achieve their three-dimensional structure, project similar surfaces to endofacial proteins that stabilize alpha(2)ARs on the surface. More rapid turnover of the alphaAR on the apical domain suggests that if such tethering proteins do exist, they may be absent or exist in a reduced density underneath the apical surface, resulting in a more rapid alphaAR turnover on the apical, when compared with the basolateral, domain.


Figure 6: Retention of the three alpha(2)AR subtypes on the basolateral surface. MDCK II permanent clonal cell lines expressing the epitope-tagged alpha(2)AR subtypes used in representative autoradiograms shown above included alpha-TAG-AR 52 (A), TAG-alphaAR 122 (B), and alpha-TAG-AR 28 (C). Polarized MDCK II cells grown on three or four 24-mm Transwell filters (depending on the clonal receptor expression) for 7 days were metabolically labeled (pulsed) with 150 µCi of [S]cysteine/methionine in 150 µl of medium for 60 min at 37 °C, 5% CO(2), and then incubated in medium supplemented with 1 mM methionine, 1 mM cysteine for various periods of time (``chase period'') at 37 °C. The 2-h chase period was designated as t(0) (time = 0) based on our previous observations of time required for the nascent alpha(2)AR to arrive at the basolateral surface. In addition to the t(0), alpha(2)ARs were also isolated following 6- and 24-h chase periods, using biotin surface labeling strategy coupled with receptor immunoisolation and streptavidin-agarose chromatography, as described under ``Experimental Procedures.'' The upper panel of A, B, and C provides autoradiograms of 7-20% gradient SDS-PAGE from a representative experiment; the lower panels show plots of the means ± S.E. of radioactivity in each band averaged from three experiments. Receptor bands were excised from autoradiograms according to the position of each alpha(2)AR subtype and counted in a beta-counter with 10 ml of scintillation liquid. The percentage of radioactivity present in each receptor band was plotted on a semi-log scale as a function of time defining radioactivity at t(0) as 100%.




SUMMARY

Fig. 7provides a schematic diagram of the different trafficking itineraries observed for the three alpha(2)AR subtypes in these studies. As described previously (8) , the alphaAR subtype is delivered directly to the basolateral membrane and at steady-state virtually all alphaAR is present on the surface. The alphaAR also is directly delivered to the basolateral surface, but at steady-state is distributed between cell surface and one or more intracellular compartments. Finally, the alphaAR subtype is initially delivered randomly to both cell surfaces but then is preferentially retained on the basolateral membrane. Although all three alpha(2)AR subtypes have been detected in renal epithelia of varying species(2, 3, 5) , the functional consequences of these differing receptor itineraries in renal epithelial cells revealed by the present studies or the implications for targeting and retention of these alpha(2)AR subtypes in other polarized cells, such as neurons, remain to be established.


Figure 7: Schematic representation of differential targeting mechanisms that lead to the basolateral localization of all three alpha(2)AR subtypes in MDCK II cells. This schematic diagram compares the targeting mechanism of the alphaAR, alphaAR, and alphaAR subtypes, and summarizes the differing trafficking or steady-state localization observed for each subtype. The alphaAR is delivered directly to the basolateral membrane (present data, (8) ). The present findings have revealed that the alphaAR is inserted randomly into both cell surface domains and is retained preferentially on the basolateral surface. At steady-state, the alphaAR and alphaAR are detected exclusively on the lateral surface of MDCK II cells, whereas the alphaAR is distributed between cell surface and intracellular compartments. However, the fraction of the alphaAR that is localized to the basolateral surface is delivered there directly.




FOOTNOTES

*
This work was supported in part by National Institutes of Health Research Grant DK 43879. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by a postdoctoral fellowship from the National Kidney Foundation.

To whom correspondence should be addressed: Dept. of Pharmacology, Vanderbilt University, School of Medicine, Nashville, TN 37232-6600. Tel.: 615-343-3533; Fax: 615-343-1084.

(^1)
The abbreviations used are: alpha(2)AR, alpha(2)-adrenergic receptor; MDCK, Madin-Darby canine kidney; [I]Rau-AzPEC, 17alpha-hydroxy-20alpha-yohimban-16beta-(N-(4-azido-3[I]-iodo)-phenethyl)-carboxamide; HA; hemagglutinin; PCR, polymerase chain reaction; bp, base pair(s); PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; BSA, bovine serum albumin; WT, wild-type; MOPS, 4-morpholinepropanesulfonic acid; FITC, fluorescein isothiocyanate.


ACKNOWLEDGEMENTS

We are grateful to Dr. Jeffrey R. Keefer for patient tutelage at the outset of these studies and sustained interest and constructive input throughout these efforts. We thank Carol Ann Bonner for superior technical assistance with the maintenance of cell lines, synthesis of the [I]Rau-AzPEC photoaffinity label, and characterization of ligand binding properties of some of the clonal cell lines used in these studies. We also thank Dr. Stephen Lanier for the Rau-NH(2)PEC precursor for Rau-AzPEC synthesis and for the cDNA encoding alphaAR. We also thank Dr. Kevin Lynch for the alphaAR cDNA. We are grateful to the members of the Limbird laboratory and Dr. Tom Jetton for helpful discussions and encouragement throughout these studies. Finally, we thank Dr. Marilyn Farquhar and Dr. Kelley Moremen for the anti-mannosidase II antibody, and Dr. Enrique Rodriguez-Boulan for the parental MDCK II cells.


REFERENCES

  1. Limbird, L. E. (1989) FASEB J. 2, 2686-2695 [Abstract/Free Full Text]
  2. Summers, R. J. (1984) Fed. Proc. 43, 2917-2922 [Medline] [Order article via Infotrieve]
  3. Matsushima, Y., Akabane, S., Kawamura, J., and Ito, K. (1987) Jpn. J. Pharmacol. 45, 284-287 [Medline] [Order article via Infotrieve]
  4. Clark, J. D., Cragoe, E. J., Jr., and Limbird, L. E. (1990) Am. J. Physiol. 259, F977-F985
  5. Uhlen, S. and Wikberg, J. E. S. (1991) Br. J. Pharmacol. 104, 657-664 [Abstract]
  6. Chan, Y. L. (1980) J. Pharmacol. Exp. Ther. 215, 65-70 [Abstract]
  7. Nord, E. P., Howard, M. J., Hafezi, A., Moradeshagi, P., Vaystula, S., and Insel, P. A. (1987) J. Clin. Invest. 80, 1755-1762 [Medline] [Order article via Infotrieve]
  8. Keefer, J. R., and Limbird, L. E. (1993) J. Biol. Chem. 268, 11340-11347 [Abstract/Free Full Text]
  9. Keefer, J. R., Kennedy, M. E., and Limbird, L. E. (1994) J. Biol. Chem. 269, 16425-16432 [Abstract/Free Full Text]
  10. Guyer, C. A., Horstman, D. A., Wilson, A. L., Clark, J. D., Cragoe, E. J., Jr., and Limbird, L. E. (1990) J. Biol. Chem. 265, 17307-17317 [Abstract/Free Full Text]
  11. Kobilka, B. K., Matsui, H., Kobilka, T. S., Yang-Feng, T. L., Francke, U., Caron, M. G., Lefkowitz, R. J., and Regan, J. W. (1987) Science 238, 650-656 [Medline] [Order article via Infotrieve]
  12. Lanier, S. M., Downing, S., Duzic, E., and Homcy, C. J. (1991) J. Biol. Chem. 266, 10470-10478 [Abstract/Free Full Text]
  13. Zeng, D., Harrison, J. K., D'Angelo, D. D., Barber, C. M., Tucker, A. L., Lu, Z. and Lynch, K. R. (1990) Pro. Natl. Acad. Sci. U. S. A. 87, 3102-3105 [Abstract]
  14. Wilson, A. L., Seibert, K., Brandon, S., Cragoe, E. J., Jr., and Limbird, L. E. (1991) Mol. Pharmacol. 39, 481-486 [Abstract]
  15. Kennedy, M. E., and Limbird, L. E. (1993) J. Biol. Chem. 268, 8003-8011 [Abstract/Free Full Text]
  16. Lanier, S. M., Homcy, C. J., Patanaude, C., and Graham, R. M. (1988) J. Biol. Chem. 263, 14491-14496 [Abstract/Free Full Text]
  17. Moremen, K. W., Touster, O., and Robbins, P. W. (1991) J. Biol. Chem. 266, 16876-16885 [Abstract/Free Full Text]
  18. Le, A., Steiner, J. L., Ferrell, G. A., Shaker, J. C., and Sifers, R. N. (1994) J. Biol. Chem. 269, 7514-7519 [Abstract/Free Full Text]
  19. Lanier, S. M., Hess, H. J., Grodski, A., and Graham, R. M. (1986) Mol. Pharmacol. 29, 219-227 [Abstract]
  20. Lanier, S. M. (1995) Pharmacol. Commun. 6, 133-137
  21. von Zastrow, M., Link, R., Daunt, D., Barsh, G., and Kobilka, B. (1993) J. Biol. Chem. 268, 763-766 [Abstract/Free Full Text]
  22. Thigpen, A. E., Cala, K. M., and Russell, D. W. (1993) J. Biol. Chem. 268, 17404-17412 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.